October
2004 | Vol. 6, No. 3
1 AMA PRA Category 1 Credit
Table of Contents
Gemcitabine in Combination With Oxaliplatin for Patients With Advanced/Metastatic Non–Small-Cell Lung Cancer
Rogerio C. Lilenbaum, MD
Update on Pemetrexed in Advanced Malignant Pleural Mesothelioma and Non–Small-Cell Lung Cancer
Mario Meyer, MD
Harit Suwanrusme, MD
Mark R. Green, MD
Molecular Profiling of Human Lung Cancer
David P. Carbone, MD, PhD
Learning Objectives | Back to top
Upon completion of this learning material, physicians should be able to:
- Assess the safety and activity of novel chemotherapy combinations in advanced NSCLC
- Compare the safety profiles and outcomes of pemetrexed with that of docetaxel in second-line therapy of advanced NSCLC
- Describe the technologies used to study protein expression patterns
in tumor tissue
Activity Goals | Back to top
Lung cancer remains the single largest cause of cancer-related mortality in the United States. Most of the approximately 175,000 patients estimated to be diagnosed with lung cancer in 2004 will be diagnosed at an advanced stage. It is agreed that a platinum-containing doublet can extend survival and improve quality of life for these patients. However, in advanced stages, lung cancer is rarely cured, and survival time is generally < 1 year. Combinations including the third-generation platinum oxaliplatin and antimetabolite-containing regimens might provide additional treatment options for patients with relapsed/refractory non–small-cell lung cancer (NSCLC).
In addition to searching for better therapies, research is also ongoing using gene and protein expression profiling to lead to a better understanding of lung cancer biology. These advances could in turn result in better prognostic factors and, ultimately, the individualizing of therapy.
The purpose of this activity is to update physicians on ongoing research in both the biology and treatment of lung cancer.
Target Audience | Back to top
This publication is intended for medical oncologists involved in the care of patients with lung cancer. No specific skills or knowledge other than a basic training in oncology are required for successful participation in this activity.
Accreditation | Back to top
Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education
for physicians.
Physicians’ Education Resource designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
Release date: October 31, 2004 Expiration date: October 31, 2005
Disclosure Policy | Back to top
As a sponsor accredited by the Accreditation Council for Continuing Medical Education, Physicians’ Education Resource must ensure balance, independence, objectivity and scientific rigor in all its sponsored activities. All faculty participating in a sponsored activity are expected to disclose to the activity audience any significant financial interest or other relationship (1) with the manufacturer(s) of any commercial product(s) and (2) with any commercial supporters of the activity. (Significant financial interest or other relationships can include such things as grants or research support, employee, consultant, major stockholder, member of speaker’s bureau, etc.) The intent of this disclosure is not to prevent an author with a significant financial or other relationship from publishing an article, but rather to provide readers with information on which they can make their own judgements. It remains for the readers to determine whether the author’s interests or relationships may influence the publication with regard to exposition or conclusion.
Rogerio C. Lilenbaum, MD
Grant or Research Support – Lilly Oncology, Sanofi-Synthelabo Inc.
Paid Consultant – Lilly Oncology Speaker’s Bureau – Lilly Oncology
Mario Meyer, MD
Has nothing to disclose
Harit Suwanrusme, MD
Has nothing to disclose
Mark R. Green, MD
Grant or Research Support — GlaxoSmithKline, Millennium Pharmaceuticals, Inc.Paid Consultant — AstraZeneca, Aventis Oncology, Genentech/OSI Pharmaceuticals, GlaxoSmithKline, Ligand Pharmaceuticals, Lilly Oncology, Novartis Oncology, Pfizer Inc. Speaker's Bureau — AstraZeneca, Aventis Oncology, Genentech/OSI Pharmaceuticals, GlaxoSmithKline, Lilly Oncology, Novartis Oncology, Pfizer Inc.Major Stock or Investment Holder — Amgen, Lilly Oncology, Pfizer Inc.
David P. Carbone, MD, PhD
Financial Consideration — AstraZeneca
The articles in this CME activity might include discussion of investigational and/or unlabeled uses of drugs. If an article includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the title page. Please refer to the full prescribing information for each drug discussed in this newsletter for FDA-approved dosing, indications, and warnings.
Advances in Lung Cancer (ISSN: 1529-4196) is produced by Physicians’ Education Resource, Dallas, TX. An unrestricted educational grant for this publication was provided by Lilly Oncology.
The views and opinions expressed in this publication are those of the authors and do not necessarily reflect the views of the sponsor or publisher. Although great care has been taken in compiling and checking the information given in this publication to ensure accuracy, the authors, Lilly Oncology, and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this publication, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.
Please consult full prescribing information for any drugs or procedures discussed within.
All rights reserved. No part of this publication may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.
©Copyright 2004 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.
All correspondence should be directed to:
Editor, Advances in Lung Cancer
Physicians’ Education Resource
3535 Worth St.
Suite 4802
Dallas, TX 75246
Phone: (214) 820-8079
Fax: (214) 820-8844
E-mail: CME@pergrouplp.com
Editorial Staff:
Publishing Manager – B. Diane Gambill, PhD
Assistant Publishing Manager – David Lee, PhD
Managing Editor – Jennifer Klem, PhD
Manager, CME and Content – Preeta Tyagi, PhD
Senior Medical Editor – Jay Delmar, PhD
Associate Medical Editor – Jill Cowherd
Medical Editor/Proofreader – Pete Sloan
Acquisitions – Anissa Mitchell
Design & Production:
Art Director – Todd J. Hagler
Senior Graphic Artist – Kelly D. Martin
Graphic Artist – Kevin Graves
Web Developer – Jason Salamone
ISSN: 1529-4196
Back to top
|
